F0806
Factor IX human
aqueous glycerol solution, ≥145 units/mg protein
Synonym(s):
Christmas factor, Plasma thromboplastin component
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
human
Quality Level
form
aqueous glycerol solution
specific activity
≥145 units/mg protein
mol wt
55 kDa
technique(s)
ligand binding assay: suitable
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... F9(2158)
Looking for similar products? Visit Product Comparison Guide
General description
Factor IX is a 55 kDa single chain vitamin K-dependent plasma zymogen which plays a key role in the intrinsic and extrinsic blood coagulation systems.
Application
Factor IX is plasma zymogen key to blood coagulation systems. It has been used in studies of portal vein thrombosis (PVT) in hepatocellular carcinoma (HCC). It has been found that abnormalities in factor IX contribute to PVT in HCC patients. Additionally, it has been used in studies of changes in the coagulation system in patients with inflammatory bowel disease (IBD).
Linkage
View this factors role in the Coagulation Cascade
Unit Definition
One unit is equivalent to the Factor IX activity in 1.0 mL of normal human plasma at pH 7.4 at 37 °C.
Physical form
Aqueous solution containing 50% (v/v) glycerol
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Storage Class Code
10 - Combustible liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Uri Martinowitz et al.
Thrombosis research, 131 Suppl 2, S11-S14 (2013-03-30)
Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) is a novel recombinant albumin fusion protein designed to extend the half-life of recombinant factor IX (rFIX), which is used in the management of hemophilia B. Clinical evaluation of rIX-FP
Elena Santagostino
Thrombosis research, 131 Suppl 2, S7-10 (2013-03-30)
Hemophilia B is a severe bleeding disorder that is characterized by a deficiency or dysfunction of coagulation factor IX (FIX). Replacement therapy using recombinant or plasma-derived FIX is available, but the relatively short half-life of FIX (approximately 18 hours) necessitates
Priya Verghese et al.
Pediatric nephrology (Berlin, Germany), 28(5), 823-826 (2013-02-06)
Nephrotic syndrome (NS) is a recognized complication of immune tolerance induction (ITI) therapy, a treatment strategy used to treat inhibitors in patients with hemophilia B receiving factor IX concentrate. We present a 4-year-old boy with hemophilia B and an inhibitor
Cassandra L Pegg et al.
Glycoconjugate journal, 37(4), 471-483 (2020-05-08)
Human Factor IX is a highly post-translationally modified protein that is an important clotting factor in the blood coagulation cascade. Functional deficiencies in Factor IX result in the bleeding disorder haemophilia B, which is treated with plasma-derived or recombinant Factor
Mariko Yamamoto et al.
[Rinsho ketsueki] The Japanese journal of clinical hematology, 54(3), 300-304 (2013-05-17)
This report describes the successful management of neurosurgical procedures with continuous infusion of recombinant factor IX (rFIX). A 1-year-old boy with severe hemophilia B was administered prophylactic therapy with rFIX after intracranial bleeding. We found the enlargement of an arachnoid
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service